Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855228 | 0.83 | TAAR1 (0.54) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL17542524 | 0.83 | TAAR1 (0.54) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL16203413 | 0.83 | TAAR1 (0.54) | FPR2MMEACECPA1ACE2 | |
| SCHEMBL14640271 | 0.83 | FPR2 (0.60) | FPR2GPR132ACE | |
| SCHEMBL9957508 | 0.83 | ACE (0.59) | FPR2GPR132ACE | |
| SCHEMBL9957511 | 0.83 | ACE (0.59) | FPR2GPR132ACE | |
| SCHEMBL27127274 | 0.81 | FPR2 (0.55) | FPR2MAPK14GPR132MMEACE | |
| SCHEMBL26985868 | 0.81 | FPR2 (0.55) | FPR2MAPK14GPR132MMEACE | |
| SCHEMBL31688647 | 0.80 | PPARA (0.53) | GPR132MMEACECPA1ACE2 | |
| SCHEMBL22444621 | 0.80 | HTR2A (0.55) | FPR2CYP2C9CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FPR2 1502/4885MAPK14 179/4885CYP2C9 4569/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | FPR2 1502/4885MAPK14 179/4885CYP2C9 4569/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | FPR2 541/4885MAPK14 331/4885CYP2C9 2564/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | FPR2 1502/4885MAPK14 179/4885CYP2C9 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.